Lantern Pharma (NASDAQ:LTRN – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), FiscalAI reports.
Lantern Pharma Trading Down 6.2%
Shares of NASDAQ LTRN traded down $0.02 during trading on Tuesday, reaching $0.36. 92,928 shares of the company traded hands, compared to its average volume of 306,371. The stock has a market cap of $5.45 million, a P/E ratio of -0.23 and a beta of 2.48. The firm’s fifty day simple moving average is $0.95 and its 200 day simple moving average is $2.32. Lantern Pharma has a 12-month low of $0.36 and a 12-month high of $4.34.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on LTRN. Weiss Ratings lowered shares of Lantern Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 11th. Wall Street Zen lowered Lantern Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock has an average rating of “Sell”.
Read Our Latest Analysis on LTRN
Lantern Pharma Company Profile
Lantern Pharma is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. It uses its artificial intelligence and machine-learning platform, RADR, to analyze cancer data and help identify drug candidates, potential biomarkers and patient groups that may respond to treatment. The company’s development pipeline includes investigational therapies for several cancers. Its candidates include LP-300, being studied for certain patients with non-small cell lung cancer, and LP-184 and LP-284, which are being developed for selected solid tumors and blood cancers.
Read More
- Five stocks we like better than Lantern Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
